StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
ABBVBullishIndustry Newsnews
High materiality9/10

AbbVie sees strong DLBCL PFS improvement with epcoritamab-lenalidomide in Phase 3

Jun 29, 2026, 4:20 PM EDT2 sourcesAI-analyzed
Why it may matterVerify against the original reporting

Positive Phase 3 topline data for a high-profile oncology asset can prompt a near-term re-rating, especially with a clear regulatory path ahead and potential label expansion via collaboration.

AI summary

What happened, with direct paths to the underlying reporting

AbbVie reported positive Phase 3 EPCORE-4 topline results for epcoritamab plus lenalidomide in relapsed/refractory DLBCL, showing significantly improved PFS versus R-GemOx (US HR 0.40; outside US 0.44; p<0.0001). Safety aligned with known profiles. AbbVie and Genmab will pursue regulatory discussions, with data to be presented at future meetings. Potentially expands epcoritamab's label and collaboration-driven growth.

  • Phase 3 EPCORE-4: epcoritamab + lenalidomide improves PFS. HR US 0.40; global 0.44.
  • Safety profile aligns with known data; no new safety signals.
  • Regulators to discuss next steps; data to be presented at future meetings.
  • AbbVie-Genmab collaboration supports broader epcoritamab commercialization.
  • Topline: June 29, 2026.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event